Potential Beneficial Effects of Granulocyte Colony-Stimulating Factor Therapy for Spastic Paraparesis in a Patient with Kyphoscoliosis: A Case Report

Abstract

Congenital kyphosis and kyphoscoliosis are much less common than congenital scoliosis and more serious because these curves can progress rapidly and can lead to spinal cord compression and paraplegia. A 15-year-old boy presented with congenital kyphoscoliosis along with spastic paraparesis (American Spinal Injury Association Impairment Scale grade C). We examined the safety and effectiveness of a low dose of analog granulocyte colony-stimulating factor (G-CSF) in this patient. G-CSF 5 µg/kg was given subcutaneously, daily for 5 days per month for 3 months. Laboratory tests, including blood, biochemical tests, and CD34+ cells (marker hematopoietic progenitor cells) were performed, in addition to clinical examination. Clinical examination revealed an increase of muscle strength in the upper limbs and decrease spasticity in the lower limbs between baseline and day 90 and day 180. We found no serious adverse event, drug-related platelet reduction, or splenomegaly. Leukocyte levels remained below 21,000/µL. CD34+ increased significantly at day 5 of G-CSF administration. Low-dose G-CSF was safe and well tolerated by the patient. A significant increase in muscle strength in this patient with spastic paraparesis after 3 months of treatment may indicate beneficial effects of G-CSF factor in this disorder. These results are inspiring and warrant further studies.

Keywords

boy - congenital kyphoscoliosis - spastic paraparesis - granulocyte colony-stimulating factor - CD34+ - muscle strength

• References

• 1 Hedequist D, Emans J. Congenital scoliosis. J Am Acad Orthop Surg 2004; 12 (4) 266-275
• 2 McMaster MJ, Singh H. Natural history of congenital kyphosis and kyphoscoliosis. A study of one hundred and twelve patients. J Bone Joint Surg Am 1999; 81 (10) 1367-1383
• 3 Okurowska-Zawada B, Kułak W, Sienkiewicz D, Paszko-Patej G. Progressive paraparesis in 14 - year-old male with kyphoscoliosis: A case report. Prog Health Sci 2012; 2 (2) 203-206
• 4 Hara M, Yuasa S, Shimoji K , et al. G-CSF influences mouse skeletal muscle development and regeneration by stimulating myoblast proliferation. J Exp Med 2011; 208 (4) 715-727
• 5 Buckingham M, Montarras D. Skeletal muscle stem cells. Curr Opin Genet Dev 2008; 18 (4) 330-336
• 6 Scheib J, Höke A. Advances in peripheral nerve regeneration. Nat Rev Neurol 2013; 9 (12) 668-676
• 7 Ruozi B, Belletti D, Bondioli L , et al. Neurotrophic factors and neurodegenerative diseases: a delivery issue. Int Rev Neurobiol 2012; 102: 207-247
• 8 Koda M, Nishio Y, Kamada T , et al. Granulocyte colony-stimulating factor (G-CSF) mobilizes bone marrow-derived cells into injured spinal cord and promotes functional recovery after compression-induced spinal cord injury in mice. Brain Res 2007; 1149: 223-231
• 9 Sakuma T, Yamazaki M, Okawa A , et al. Neuroprotective therapy using granulocyte colony-stimulating factor for patients with worsening symptoms of thoracic myelopathy: a multicenter prospective controlled trial. Spine 2012; 37 (17) 1475-1478
• 10 Kato K, Yamazaki M, Okawa A , et al. Intravenous administration of granulocyte colony-stimulating factor for treating neuropathic pain associated with compression myelopathy: a phase I and IIa clinical trial. Eur Spine J 2013; 22 (1) 197-204